^
Association details:
| Biomarker: | EGFR G719A + EGFR R776C |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations
Published date:
03/01/2022
Excerpt:
A case of a lung SCC patient harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib...This case first identified a patient with lung squamous cell carcinoma harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib and achieved 11 months of progression-free survival (PFS).
DOI:
https://doi.org/10.1007/s00432-021-03864-4
